article = {DDA-2020-1-104}
title = {Ribonucleases and Immunoribonucleases as Potential Modalities of Anticancer Therapy}
journal = {Drug and Drug Abuse}
year = {2020}
issn = {2674-5062}
doi = {http://dx.doi.org/10.31487/j.DDA.2020.01.04}
url = {https://www.sciencerepository.org/ribonucleases-and-immunoribonucleases-as-potential-modalities-of-anticancer-therapy_DDA-2020-1-104 
author = {Monika  Kowalik,Magdalena Witkowska,Piotr Smolewski,}
keywords = {Rana pipiens, onconase, r-amphinase, ribonuclease, immunoRNases, apoptosis, anticancer properties}
abstract ={A novel approach of antitumor treatment, that involves targeting RNA either using specific antisense
oligonucleotides or cytostatic/cytotoxic ribonucleases (RNases), is being promoted. Among recently
described cytotoxic RNases, amphibian RNases, including ranpirnase (onconase; ONC) and Amphinase (rAmph), are promising anticancer agents. They manifest strong antitumor effects and act synergistically with
several cytostatics. Recently, rapidly developed proteins by engineering of RNases, displayed cytotoxic
activity against several types of malignant cells. Most recent data show the role of microRNAs in mediating
tumor progression, opening a new field of possible molecular targets for RNases. This review summarizes
the current status of those RNases and immunoRNases as promising novel anticancer therapeutics.}